These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2332786)

  • 1. In-vitro evaluation of a new oral cephalosporin, cefroxadine (CGP 9000).
    Shibl AM; Durgham SM
    J Chemother; 1990 Feb; 2(1):8-10. PubMed ID: 2332786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model.
    Schneider P; Tosch W; Maurer M; Zak O
    J Antibiot (Tokyo); 1982 Jul; 35(7):843-9. PubMed ID: 7174537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefroxadine (CGP-9000), an orally active cephalosporin.
    Yasuda K; Kurashige S; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Jul; 18(1):105-10. PubMed ID: 6998373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a new cephalosporin, CGP 9000 (cefroxadine), in healthy volunteers.
    Bergan T
    Chemotherapy; 1980; 26(4):225-30. PubMed ID: 7389422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of cefroxadine in the field of obstetrics and gynecology].
    Motomori R; Takahashi H; Yamamoto J; Yamasaki F
    Jpn J Antibiot; 1983 Sep; 36(9):2562-70. PubMed ID: 6655871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of microbiological and high pressure liquid chromatographic assays of the new cephalosporin cefroxadine.
    Bergan T; Solberg R
    Methods Find Exp Clin Pharmacol; 1981; 3(3):179-82. PubMed ID: 7253774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effect of cefroxadine on surgical infections].
    Aikawa T; Noguchi S; Fujimoto N; Mizushima H; Shibata N; Tomita N; Horii A
    Jpn J Antibiot; 1983 Sep; 36(9):2521-8. PubMed ID: 6686263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A study of the disc sensitivity test for cephradine].
    Kanazawa Y; Kuramata T; Matsumoto K
    Jpn J Antibiot; 1982 Jul; 35(7):1722-9. PubMed ID: 7176072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporin.
    Jones RN; Erwin ME
    J Clin Microbiol; 1992 May; 30(5):1297-300. PubMed ID: 1583135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of cefroxadine in the field of pediatrics (author's transl)].
    Iwai N; Sasaki A; Taneda Y; Inokuma K; Nakamura H
    Jpn J Antibiot; 1981 Dec; 34(12):1663-79. PubMed ID: 7334591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C
    J Clin Microbiol; 1986 Mar; 23(3):634-6. PubMed ID: 3754266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fundamental and clinical studies of cefroxadine in pediatric field (author's transl)].
    Toyonaga Y; Kurosu Y; Hori M; Kohno S
    Jpn J Antibiot; 1981 Dec; 34(12):1608-25. PubMed ID: 7334586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of cefroxadine in surgical infections].
    Hirayama T; Kikuchi K
    Jpn J Antibiot; 1983 Jun; 36(6):1435-8. PubMed ID: 6655799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.
    Jones RN; Barry AL; Pfaller M; Allen SD; Ayers LW; Fuchs PC
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):59-63. PubMed ID: 3370932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of cefroxadine in the field of obstetrics and gynecology].
    Uchida S; Hayashi H; Tominaga M; Kohno K; Matsunaga M; Kudo S; Kawamura R
    Jpn J Antibiot; 1983 Sep; 36(9):2549-55. PubMed ID: 6655869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CGP 9000: a new orally active, broad-spectrum cephalosporin.
    Zak O; Vischer WA; Schenk C; Tosch W; Zimmermann W; Regös J; Suter ER; Kradolfer F; Gelzer J
    J Antibiot (Tokyo); 1976 Jun; 29(6):653-5. PubMed ID: 950320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of cefroxadine dry syrup in pediatric field (author's transl)].
    Minamitani M; Hachimori K; Suzuki M; Minamikawa I
    Jpn J Antibiot; 1981 Dec; 34(12):1626-33. PubMed ID: 7334587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental and clinical evaluation of cefroxadine in the field of obstetrics and gynecology].
    Cho N; Araki H; Ishikawa T; Kunii K; Fukunaga K; Deguchi K
    Jpn J Antibiot; 1983 Sep; 36(9):2535-48. PubMed ID: 6655868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretive criteria for disk diffusion tests using 5-microgram cefdinir disks with rapidly growing clinical isolates.
    Jones RN; Erwin ME; Gooding BB
    J Clin Microbiol; 1992 Apr; 30(4):1022-3. PubMed ID: 1572959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the transfer of cefroxadine to human tears].
    Hara J; Tanaka Y; Harino S; Deguchi K
    Jpn J Antibiot; 1985 Feb; 38(2):230-4. PubMed ID: 4009946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.